Skip to main content
news)

NEWS

Media Contacts:

Europe

Emmanuella Dekonor
Mobile: +44 7920500496 
Email: Emmanuella.Dekonor@seqirus.com

United States

Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com

Asia Pacific

Joanne Cleary
Mobile: +61 428 816 751
Email: Joanne.Cleary@seqirus.com

Seqirus news releases

Seqirus news releases

Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)
19 Aug 2021

• Appoints Roberta Duncan as new program lead to drive technology advancement
• Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza

Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season
27 Jul 2021

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic.

Seqirus strengthens U.K. influenza vaccine response as high-speed fill and finish facility begins rolling 30 million doses in Liverpool
01 Jun 2021

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.

CSL Named as One of the World’s Best Employers
29 Oct 2020

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

This EU Flu Day, Seqirus confirms record number of influenza vaccines delivered across Europe to meet increased demand
14 Oct 2020

The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza vaccines on schedule, across Europe

CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia
07 Sep 2020

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19 vaccine candidate (V451), and a separate HoA with AstraZeneca to manufacture the Oxford University candidate (AZD1222), should clinical trials of both prove successful.

First adjuvanted quadrivalent influenza vaccine receives EU approval
08 Jun 2020

This news release is intended for medical, pharmaceutical industry and business media

The CSL Group collaborates with Global Plasma Leaders to accelerate development of potential COVID-19 Hyperimmune therapy
06 Apr 2020

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

COVID-19 Update
03 Apr 2020

Safeguarding our people and communities remains our top priority.

Seqirus announces positive CHMP Opinion for its adjuvanted quadrivalent influenza vaccine
31 Mar 2020

This news release is intended for medical and pharmaceutical trade media and financial media only

The CSL Group Offer To Help Battle Coronavirus
23 Mar 2020

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.

New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine
09 Dec 2019

Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine (TIV)

Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
26 Sep 2019

The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.